Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026)

Protagonist Therapeutics has reported Free Cash Flow for 12 years, with the latest figure at -$49.1 million in Q1 2026.

• Quarterly Free Cash Flow fell 139.3% year-over-year to -$49.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.8 million (down 135.13% YoY) and the FY2025 annual result came in at $56.1 million, down 69.32% from the prior year.
• Free Cash Flow declined to -$49.1 million in Q1 2026 per PTGX's latest filing, from -$38.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $268.6 million in Q2 2024 and troughed at -$49.1 million in Q1 2026.
• A 5-year average of $636705.9 and a median of -$27.7 million in 2024 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 1116.84% in 2024, down 274.06% in 2024.
• Over 5 years, Free Cash Flow stood at -$31.6 million in 2022, then soared by 153.62% to $16.9 million in 2023, then plunged by 274.06% to -$29.5 million in 2024, then sank by 30.75% to -$38.6 million in 2025, then decreased by 27.22% to -$49.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$49.1 million, -$38.6 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.